NASDAQ:IONS - Ionis Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $45.50
Forecasted Upside: 0.35 %
Number of Analysts: 10
Breakdown:
3 Sell Ratings
1 Hold Ratings
6 Buy Ratings
0 Strong Buy Ratings

^$45.34 As of 08/11/2022 11:39 AM ET

▼ -0.77 (-1.67%)

1 month | 3 months | 12 months

Get New Ionis Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for IONS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IONS

^$45.50

▲ +0.35% Upside Potential

This price target is based on 10 analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $45.50, with a high forecast of $65.00 and a low forecast of $27.00. The average price target represents a 0.35% upside from the last price of $45.34.

Current Consensus is Hold

The current consensus among 10 investment analysts is to hold stock in Ionis Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
5 hold ratings
2 sell ratings

Ratings as of

2/16/2021

0 strong buy ratings
7 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

5/17/2021

0 strong buy ratings
6 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

8/15/2021

0 strong buy ratings
5 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

11/13/2021

0 strong buy ratings
5 buy ratings
3 hold ratings
2 sell ratings

Ratings as of

2/11/2022

0 strong buy ratings
4 buy ratings
1 hold ratings
3 sell ratings

Ratings as of

5/12/2022

0 strong buy ratings
4 buy ratings
1 hold ratings
3 sell ratings

Ratings as of

7/11/2022

0 strong buy ratings
6 buy ratings
1 hold ratings
3 sell ratings

Ratings as of

8/10/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/10/2022	Citigroup	Boost Price Target	Sell	$26.00 ➝ $28.00	Low
7/26/2022	Piper Sandler	Boost Price Target	Overweight	$55.00 ➝ $58.00	Low
7/18/2022	Oppenheimer	Reiterated Rating	Outperform	$59.00	Low
6/21/2022	SVB Leerink	Boost Price Target	Market Perform	$26.00 ➝ $27.00	Low
6/10/2022	Piper Sandler	Boost Price Target		$54.00 ➝ $55.00	High
5/5/2022	Stifel Nicolaus	Boost Price Target		$31.00 ➝ $33.00	Low
4/1/2022	SVB Leerink	Lower Price Target	Market Perform	$29.00 ➝ $26.00	High
3/1/2022	Guggenheim	Initiated Coverage	Buy	$64.00	Medium
2/28/2022	Citigroup	Initiated Coverage	Sell	$26.00	Medium
2/25/2022	SVB Leerink	Lower Price Target	Market Perform	$34.00 ➝ $29.00	Medium
2/1/2022	Bank of America	Downgrade	Buy ➝ Underperform	$40.00 ➝ $30.00	High
12/17/2021	SVB Leerink	Lower Price Target	Market Perform	$36.00 ➝ $34.00	High
12/14/2021	William Blair	Upgrade	Market Perform ➝ Outperform		High
12/10/2021	BMO Capital Markets	Initiated Coverage	Buy	$65.00	Medium
12/8/2021	SVB Leerink	Lower Price Target	Market Perform	$39.00 ➝ $36.00	High
11/4/2021	Needham & Company LLC	Lower Price Target	Buy	$84.00 ➝ $60.00	Medium
11/4/2021	SVB Leerink	Boost Price Target	Market Perform	$38.00 ➝ $39.00	Medium
10/12/2021	Morgan Stanley	Lower Price Target	Underweight	$33.00 ➝ $31.00	Low
8/19/2021	BMO Capital Markets	Lower Price Target	Outperform	$70.00 ➝ $68.00	Low
8/5/2021	SVB Leerink	Lower Price Target	Market Perform	$41.00 ➝ $38.00	High
7/16/2021	Morgan Stanley	Lower Price Target	Underweight	$35.00 ➝ $33.00	Medium
5/14/2021	SVB Leerink	Boost Price Target	Market Perform	$36.00 ➝ $41.00	Medium
5/7/2021	UBS Group	Upgrade	Sell ➝ Neutral	$33.00 ➝ $37.50	High
5/6/2021	Morgan Stanley	Lower Price Target	Underweight	$38.00 ➝ $35.00	High
4/19/2021	Morgan Stanley	Lower Price Target	Underweight	$43.00 ➝ $38.00	Low
4/5/2021	UBS Group	Reiterated Rating	Reduce		High
3/23/2021	BMO Capital Markets	Lower Price Target	Positive ➝ Outperform	$90.00 ➝ $76.00	High
3/23/2021	Needham & Company LLC	Lower Price Target	Buy	$95.00 ➝ $86.00	High
3/23/2021	SVB Leerink	Lower Price Target	Market Perform	$50.00 ➝ $36.00	High
3/23/2021	Morgan Stanley	Lower Price Target	Underweight	$50.00 ➝ $43.00	High
3/23/2021	Barclays	Lower Price Target	Equal Weight	$52.00 ➝ $47.00	High
3/23/2021	Royal Bank of Canada	Lower Price Target	Positive ➝ Outperform	$76.00 ➝ $65.00	High
3/22/2021	Piper Sandler	Lower Price Target	Neutral	$55.00 ➝ $45.00	High
3/16/2021	UBS Group	Reiterated Rating	Sell	$33.00	Medium
3/1/2021	Barclays	Upgrade	Underweight ➝ Equal Weight	$50.00 ➝ $52.00	Low
2/25/2021	Morgan Stanley	Boost Price Target	Underweight	$49.00 ➝ $50.00	High
2/24/2021	Piper Sandler	Lower Price Target	Neutral	$60.00 ➝ $55.00	High
12/15/2020	UBS Group	Initiated Coverage	Sell	$34.00	Medium
12/15/2020	Cowen	Upgrade	Market Perform ➝ Outperform		High
11/5/2020	Morgan Stanley	Lower Price Target	Underweight	$50.00 ➝ $49.00	High
11/5/2020	SVB Leerink	Lower Price Target	Market Perform	$56.00 ➝ $50.00	High
10/13/2020	Morgan Stanley	Lower Price Target	Underweight	$54.00 ➝ $50.00	Low
10/7/2020	Oppenheimer	Reiterated Rating	Buy	$69.00	Low
9/22/2020	Oppenheimer	Initiated Coverage	Buy	$69.00	High
9/22/2020	Cantor Fitzgerald	Boost Price Target	Neutral	$56.00 ➝ $59.00	High
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		Medium
9/8/2020	Citigroup	Lower Price Target		$74.00 ➝ $78.00	Low
9/2/2020	Benchmark	Initiated Coverage	Hold		Medium
9/1/2020	Royal Bank of Canada	Boost Price Target		$71.00 ➝ $73.00	Low
9/1/2020	SVB Leerink	Boost Price Target	Market Perform	$54.00 ➝ $56.00	Medium
9/1/2020	Oppenheimer	Lower Price Target	Outperform	$74.00 ➝ $69.00	Medium
9/1/2020	Needham & Company LLC	Boost Price Target	Buy	$89.00 ➝ $91.00	Medium
8/30/2020	Oppenheimer	Initiated Coverage	Buy	$74.00	High
8/10/2020	Citigroup	Lower Price Target	Buy	$80.00 ➝ $78.00	High
8/6/2020	Morgan Stanley	Lower Price Target	Underweight	$56.00 ➝ $54.00	Low
8/6/2020	Oppenheimer	Reiterated Rating	Buy		Low
8/5/2020	Needham & Company LLC	Initiated Coverage	Buy	$89.00	Low
8/5/2020	William Blair	Reiterated Rating	Hold		Low
7/15/2020	Morgan Stanley	Boost Price Target	Underweight	$51.00 ➝ $56.00	Low
7/15/2020	Needham & Company LLC	Reiterated Rating	Buy	$89.00	Medium
6/10/2020	William Blair	Reiterated Rating	Hold		High
6/5/2020	Citigroup	Boost Price Target	Buy	$71.00 ➝ $80.00	High
5/12/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$71.00	Medium
5/7/2020	Morgan Stanley	Boost Price Target	Underweight	$48.00 ➝ $51.00	High
5/7/2020	Oppenheimer	Lower Price Target	Outperform	$77.00 ➝ $74.00	High
5/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$89.00	High
4/9/2020	Citigroup	Lower Price Target	Buy	$73.00 ➝ $71.00	Low
3/26/2020	Cantor Fitzgerald	Lower Price Target	Neutral	$65.00 ➝ $56.00	High
3/9/2020	JPMorgan Chase & Co.	Boost Price Target	Neutral	$58.00 ➝ $60.00	Low
3/5/2020	Citigroup	Initiated Coverage	Buy	$73.00	High
2/27/2020	Piper Sandler	Lower Price Target	Neutral	$70.00 ➝ $65.00	High
1/30/2020	BMO Capital Markets	Reiterated Rating	Buy	$86.00	High
1/24/2020	William Blair	Reiterated Rating	Hold		Low
12/31/2019	Bank of America	Reiterated Rating	Buy	$70.00	Medium
12/23/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Low
12/13/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Medium
12/12/2019	Oppenheimer	Initiated Coverage	Buy	$77.00	Low
11/14/2019	William Blair	Initiated Coverage	Market Perform		Low
11/13/2019	Bank of America	Initiated Coverage	Buy	$70.00	Medium
11/7/2019	Piper Jaffray Companies	Lower Price Target	Neutral	$75.00 ➝ $70.00	Medium
11/7/2019	Needham & Company LLC	Reiterated Rating	Buy	$87.00	Low
11/7/2019	Morgan Stanley	Downgrade	Equal ➝ Equal Weight	$63.00 ➝ $48.00	Low
11/7/2019	Cowen	Reiterated Rating	Hold		Low
10/16/2019	Cowen	Reiterated Rating	Hold		High
10/15/2019	Cantor Fitzgerald	Set Price Target	Hold	$65.00	N/A
10/11/2019	Morgan Stanley	Lower Price Target	Equal Weight	$68.00 ➝ $63.00	Medium
10/10/2019	Wells Fargo & Company	Boost Price Target	Outperform	$90.00 ➝ $120.00	Medium
10/9/2019	Needham & Company LLC	Set Price Target	Buy	$87.00	Low
9/23/2019	Wells Fargo & Company	Reiterated Rating	Buy		Medium
9/10/2019	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$80.00	High
8/7/2019	Evercore ISI	Set Price Target	Hold	$76.00	Low
7/24/2019	BMO Capital Markets	Lower Price Target	Outperform	$96.00 ➝ $95.00	Low
5/24/2019	Piper Jaffray Companies	Set Price Target	Hold	$75.00	Medium
4/24/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$68.00	Low
4/22/2019	BMO Capital Markets	Boost Price Target	Outperform	$96.00	Low
4/18/2019	Cantor Fitzgerald	Reiterated Rating	Hold		Low
4/9/2019	Cantor Fitzgerald	Initiated Coverage	Neutral	$68.00	Medium
3/22/2019	Piper Jaffray Companies	Set Price Target	Neutral	$63.00 ➝ $75.00	Low
3/18/2019	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$47.00 ➝ $55.00	Low
3/1/2019	Morgan Stanley	Set Price Target	Hold	$71.00	Low
3/1/2019	Piper Jaffray Companies	Set Price Target	Hold	$63.00	Low
2/28/2019	Piper Jaffray Companies	Boost Price Target	Neutral	$60.00	Low
2/28/2019	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $82.00	Low
11/27/2018	SVB Leerink	Initiated Coverage	Market Perform	$50.00	High
11/7/2018	Morgan Stanley	Set Price Target	Hold	$46.00	Low
11/6/2018	Piper Jaffray Companies	Set Price Target	Hold	$50.00	Medium
10/3/2018	Morgan Stanley	Set Price Target	Hold	$45.00	Low
9/25/2018	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$45.00 ➝ $48.00	High
9/24/2018	Piper Jaffray Companies	Set Price Target	Hold	$50.00	Medium
8/28/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$49.00 ➝ $45.00	Low
8/28/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$47.00 ➝ $45.00	High
8/8/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$51.00 ➝ $49.00	High
8/7/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$55.00 ➝ $48.00	High
7/11/2018	Piper Jaffray Companies	Set Price Target	Hold	$50.00	Low
6/20/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$52.00	High
5/30/2018	Piper Jaffray Companies	Initiated Coverage	Hold	$50.00	Medium
5/7/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$52.00	Low
5/7/2018	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$57.00	Low
4/23/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00	Medium
2/28/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$64.00 ➝ $65.00	High
2/28/2018	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$55.00 ➝ $57.00	High
2/20/2018	Sanford C. Bernstein	Reiterated Rating	Market Perform	$61.00 ➝ $55.00	Low
11/8/2017	BMO Capital Markets	Boost Price Target	Outperform	$64.00 ➝ $65.00	N/A
11/8/2017	Morgan Stanley	Boost Price Target	Equal Weight	$45.00 ➝ $49.00	N/A
10/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	N/A
10/13/2017	Stifel Nicolaus	Reiterated Rating	Hold	$50.00	N/A
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Sell ➝ Sell	$30.00	N/A
10/2/2017	BMO Capital Markets	Reiterated Rating	Outperform	$69.00	Medium
9/21/2017	Barclays	Lower Price Target	Equal Weight	$55.00 ➝ $52.00	Low
9/17/2017	Needham & Company LLC	Reiterated Rating	Buy	$64.00	Low
9/12/2017	Stifel Nicolaus	Reiterated Rating	Hold		Low
9/6/2017	Barclays	Initiated Coverage	Equal Weight	$55.00	Medium
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$65.00	Low
8/14/2017	Laidlaw	Reiterated Rating	Buy	$65.00	Low
8/14/2017	BMO Capital Markets	Boost Price Target	Outperform	$67.00 ➝ $69.00	Low

(Data available from 8/11/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

2 very positive mentions
11 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/13/2022

3 very positive mentions
13 positive mentions
4 negative mentions
1 very negative mentions

Mentions as of

2/12/2022

2 very positive mentions
4 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/14/2022

4 very positive mentions
4 positive mentions
5 negative mentions
0 very negative mentions

Mentions as of

4/13/2022

0 very positive mentions
11 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

5/13/2022

0 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

6/12/2022

9 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

7/12/2022

5 very positive mentions
24 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

8/11/2022

Current Sentiment

Recent Stories by Sentiment

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Today's Range

Now: $45.34

$45.34

$46.13

50 Day Range

MA: $37.90

$33.50

$46.11

52 Week Range

Now: $45.34

$25.04

$46.15

Volume

3,407 shs

Average Volume

932,855 shs

Market Capitalization

$6.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?: The following equities research analysts have issued research reports on Ionis Pharmaceuticals in the last year: Bank of America Co., BMO Capital Markets, Citigroup Inc., Guggenheim, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, and William Blair.
View the latest analyst ratings for IONS.
What is the current price target for Ionis Pharmaceuticals?: 10 Wall Street analysts have set twelve-month price targets for Ionis Pharmaceuticals in the last year. Their average twelve-month price target is $45.50, suggesting a possible upside of 0.4%. BMO Capital Markets has the highest price target set, predicting IONS will reach $65.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $27.00 for Ionis Pharmaceuticals in the next year.
View the latest price targets for IONS.
What is the current consensus analyst rating for Ionis Pharmaceuticals?: Ionis Pharmaceuticals currently has 3 sell ratings, 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IONS, but not buy more shares or sell existing shares.
View the latest ratings for IONS.
What other companies compete with Ionis Pharmaceuticals?: Other companies that are similar to Ionis Pharmaceuticals include Alkermes, ChemoCentryx, Amicus Therapeutics, United Therapeutics and Dynavax Technologies. Learn More about companies similar to Ionis Pharmaceuticals.
How do I contact Ionis Pharmaceuticals' investor relations team?: Ionis Pharmaceuticals' physical mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company's listed phone number is (760) 931-9200 and its investor relations email address is [email protected] The official website for Ionis Pharmaceuticals is www.ionispharma.com. Learn More about contacing Ionis Pharmaceuticals investor relations.

NASDAQ:IONS - Ionis Pharmaceuticals Stock Price Target and Predictions

Analyst Price Target for IONS

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.42 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Ionis Pharmaceuticals?

What is the current price target for Ionis Pharmaceuticals?

What is the current consensus analyst rating for Ionis Pharmaceuticals?

What other companies compete with Ionis Pharmaceuticals?

How do I contact Ionis Pharmaceuticals' investor relations team?